Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 824 | 77 | 743 |
| Samples | 222 | 31 | 188 |
| Peptides | 181 | 26 | 157 |
Function
NARF · Nuclear prelamin A recognition factor
Several proteins have been found to be prenylated and methylated at their carboxyl-terminal ends. Prenylation was initially believed to be important only for membrane attachment. However, another role for prenylation appears to be its importance in protein-protein interactions. The only nuclear proteins known to be prenylated in mammalian cells are prelamin A- and B-type lamins. Prelamin A is farnesylated and carboxymethylated on the cysteine residue of a carboxyl-terminal CaaX motif. This post-translationally modified cysteine residue is removed from prelamin A when it is endoproteolytically processed into mature lamin A. The protein encoded by this gene binds to the prenylated prelamin A carboxyl-terminal tail domain. It may be a component of a prelamin A endoprotease complex. The encoded protein is located in the nucleus, where it partially colocalizes with the nuclear lamina. It shares limited sequence similarity with iron-only bacterial hydrogenases. Alternatively spliced transcript variants encoding different isoforms have been identified for this gene, including one with a novel exon that is generated by RNA editing. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 157 amino-acid changes on canonical ENST00000309794 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in NARF · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in NARF – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 3/40 8% | 0/0 0% |
| Endometrial Carcinoma | 2/42 5% | 10/612 2% |
| Other Solid Cancers | 2/94 2% | 18/1515 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Colorectal Carcinoma | 4/143 3% | 28/3239 1% |
| Melanoma | 0/210 0% | 18/1899 1% |
| Bladder Carcinoma | 1/58 2% | 7/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 11/1592 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 6/1390 0% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Ewings Sarcoma | 0/63 0% | 2/262 1% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Neuroendocrine Tumour | 3/154 2% | 1/577 0% |
| Hepatocellular Carcinoma | 1/46 2% | 11/2210 0% |
| Glioma | 3/52 6% | 8/2127 0% |
| Biliary Tract Carcinoma | 1/54 2% | 4/950 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Gastric Carcinoma | 0/74 0% | 8/1809 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 9/2550 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Breast Carcinoma | 0/144 0% | 10/3264 0% |
| Kidney Carcinoma | 0/85 0% | 4/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
| Other Blood Cancers | 1/61 2% | 4/2725 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 1/752 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| B-Lymphoblastic Leukemia | 0/55 0% | 2/2640 0% |
Mutation Distribution
Where NARF is mutated · all tissues, split by cell line vs tissue
How many mutations in NARF were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 824 mutations in NARF
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|